Home  »  Finance   »  Acorda Therapeutics Inc. (NASDAQ:ACOR): The Fundam...

Acorda Therapeutics Inc. (NASDAQ:ACOR): The Fundamentals Have Changed

Acorda Therapeutics Inc. (NASDAQ:ACOR) previous close was $4.10 while the outstanding shares total 9.47M. The firm has a beta of 0.64. ACOR’s shares traded higher over the last trading session, gaining 18.29% on 06/17/21. The shares fell to a low of $4.33 before closing at $4.85. Intraday shares traded counted 1.8 million, which was -751.06% lower than its 30-day average trading volume of 211.33K. The stock’s Relative Strength Index (RSI) is 68.62, with weekly volatility at 10.63% and ATR at 0.32. The ACOR stock’s 52-week price range has touched low of $2.53 and a $9.84 high.

Investors have identified the Biotechnology company Acorda Therapeutics Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $45.49 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.

Acorda Therapeutics Inc. (ACOR) Fundamentals that are to be considered.

When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 189.72 million total, with 133.05 million as their total liabilities.

ACOR were able to record -26.92 million as free cash flow during the 07/29/2021 quarter of the year, this saw their quarterly net cash flow reduce by 45.54 million. In cash movements, the company had a total of -26.89 million as operating cash flow.

Potential earnings growth for Acorda Therapeutics Inc. (ACOR)

In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 07/29/2021 quarter of the year, Acorda Therapeutics Inc. recorded a total of 28.86 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 2.64% coming in sequential stages and their sales for the 07/29/2021 quarter reducing by -32.22%.

What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 11.96 million trying to sell their products during the last quarter, with the result yielding a gross income of 16.9 million. This allows shareholders to hold on to 9.47M with the recently reported earning now reading -3.53 cents per share. This is a figure that compared to analyst’s prediction for their 07/29/2021 (-3.53 cents a share).

Is the stock of ACOR attractive?

In the last 6 months, insiders have changed their ownership in shares of company stock by 1.80%.

1 out of 1 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Acorda Therapeutics Inc.. 0 analysts has assigned a Sell rating on the ACOR stock. The 12-month mean consensus price target for the company’s shares has been set at $5.00.

Leave a Comment

Your email address will not be published.